Since SNAI2 KD cells express higher levels of myogenic differentiation transcription factors MYOD, MYOG, and MEF2C, we hypothesized that combining SNAI2 silencing with a standard of care drug in RMS therapy would enhance differentiation of tumor cells often detected as nests of cells after conventional therapy27. The gene discussed is MYOD1; the disease is neoplasm.